BR112016012146A8 - derivados de aminopiridina como inibidores de quinase da família tam - Google Patents
derivados de aminopiridina como inibidores de quinase da família tamInfo
- Publication number
- BR112016012146A8 BR112016012146A8 BR112016012146A BR112016012146A BR112016012146A8 BR 112016012146 A8 BR112016012146 A8 BR 112016012146A8 BR 112016012146 A BR112016012146 A BR 112016012146A BR 112016012146 A BR112016012146 A BR 112016012146A BR 112016012146 A8 BR112016012146 A8 BR 112016012146A8
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitors
- family kinase
- aminopyridine derivatives
- tam family
- tam
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
resumo ?derivados de aminopiridina como inibidores quinase da família tam? trata-se de derivados de aminopiridina e composições farmacêuticas que sejam úteis como inibidores quinase da família tam.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361909828P | 2013-11-27 | 2013-11-27 | |
US201361909830P | 2013-11-27 | 2013-11-27 | |
US61/909,828 | 2013-11-27 | ||
US61/909,830 | 2013-11-27 | ||
PCT/US2014/067709 WO2015081257A2 (en) | 2013-11-27 | 2014-11-26 | Aminopyridine derivatives as tam family kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112016012146A2 BR112016012146A2 (pt) | 2017-08-08 |
BR112016012146A8 true BR112016012146A8 (pt) | 2018-01-30 |
BR112016012146B1 BR112016012146B1 (pt) | 2022-11-01 |
Family
ID=52146717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016012146-5A BR112016012146B1 (pt) | 2013-11-27 | 2014-11-26 | Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos |
Country Status (11)
Country | Link |
---|---|
US (4) | US10233176B2 (pt) |
EP (1) | EP3074390B1 (pt) |
JP (1) | JP6496731B2 (pt) |
KR (1) | KR102398473B1 (pt) |
CN (2) | CN105764514B (pt) |
AU (1) | AU2014354711B2 (pt) |
BR (1) | BR112016012146B1 (pt) |
CA (1) | CA2930324C (pt) |
IL (1) | IL245660B (pt) |
MX (2) | MX2016006815A (pt) |
WO (1) | WO2015081257A2 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
IL295603B2 (en) | 2017-09-22 | 2024-03-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
MX2020006812A (es) | 2017-12-26 | 2020-11-06 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
US20220356185A1 (en) * | 2018-07-06 | 2022-11-10 | Kymera Therapeutics, Inc. | Mertk degraders and uses thereof |
US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
US20220031685A1 (en) | 2018-09-18 | 2022-02-03 | Signalchem Lifesciences Corporation | Combination therapy for treating blood cancer |
EP3886904A4 (en) | 2018-11-30 | 2022-07-13 | Kymera Therapeutics, Inc. | IRAQ-TYPE KINASE DEGRADING AGENTS AND THEIR USES |
US11779578B2 (en) | 2019-12-17 | 2023-10-10 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
WO2021133920A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
JP2023518423A (ja) | 2020-03-19 | 2023-05-01 | カイメラ セラピューティクス, インコーポレイテッド | Mdm2分解剤およびそれらの使用 |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
CN112707898A (zh) * | 2020-12-21 | 2021-04-27 | 徐新杰 | 一种杂芳基取代的吡嗪衍生物及其应用 |
EP4284368A1 (en) | 2021-02-01 | 2023-12-06 | SignalChem Lifesciences Corporation | Use of the axl inhibitor slc-391 as antiviral therapeutic agent |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507080A (ja) | 2005-09-07 | 2009-02-19 | リゲル ファーマシューティカルズ,インコーポレーテッド | Axl阻害剤として有用なトリアゾール誘導体 |
PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
DE602007004092D1 (de) * | 2006-03-22 | 2010-02-11 | Vertex Pharma | C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen |
EP1900727A1 (en) * | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
US8097630B2 (en) | 2006-10-10 | 2012-01-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors |
US7879856B2 (en) | 2006-12-22 | 2011-02-01 | Rigel Pharmaceuticals, Inc. | Diaminothiazoles useful as Axl inhibitors |
CN101622248B (zh) | 2006-12-29 | 2013-04-17 | 里格尔制药公司 | 用作axl抑制剂的n3-杂芳基取代的三唑和n5-杂芳基取代的三唑 |
CN110551105B (zh) | 2006-12-29 | 2022-10-18 | 里格尔制药公司 | 用作axl抑制剂的取代三唑 |
US7709482B2 (en) | 2006-12-29 | 2010-05-04 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors |
PT2114955E (pt) | 2006-12-29 | 2013-04-18 | Rigel Pharmaceuticals Inc | Triazoles substituídos com arilo bicíclico em ponte ou heteroarilo bicíclico em ponte úteis como inibidores de axl |
WO2008083353A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
CA2682733A1 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors |
PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
GB0713259D0 (en) | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
WO2009024825A1 (en) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
MX2010004491A (es) | 2007-10-25 | 2010-06-21 | Astrazeneca Ab | Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares. |
CA2704052C (en) | 2007-10-26 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
WO2009099982A1 (en) * | 2008-02-04 | 2009-08-13 | Osi Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
US20110003859A1 (en) | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
EP2262772B8 (en) | 2008-04-16 | 2013-03-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline derivatives as axl kinase inhibitors |
US8349838B2 (en) * | 2008-07-09 | 2013-01-08 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors |
CA2730251C (en) * | 2008-07-09 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
CN102281875B (zh) | 2009-01-16 | 2017-09-22 | 里格尔药品股份有限公司 | 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法 |
JP2012517426A (ja) | 2009-02-09 | 2012-08-02 | アステックス ファーマシューティカルズ インコーポレイテッド | ピロロピリミジニルaxlキナーゼ阻害剤 |
EP2311809A1 (en) | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
SG182803A1 (en) | 2010-02-05 | 2012-09-27 | Merck Patent Gmbh | Hetaryl-[1,8]naphthyridine derivatives |
WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
EP2569284B1 (en) * | 2010-05-12 | 2015-07-08 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as inhibitors of atr kinase |
EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
WO2012087938A1 (en) | 2010-12-20 | 2012-06-28 | Glaxosmithkline Llc | Quinazolinone derivatives as antiviral agents |
PL2693881T3 (pl) | 2011-04-01 | 2020-03-31 | University Of Utah Research Foundation | Podstawione analogi N-fenylopirymidyno-2-aminy jako inhibitory kinazy AXL |
JP6051434B2 (ja) | 2011-11-14 | 2016-12-27 | イグニタ、インク. | AXLおよびc−METキナーゼ阻害剤としてのウラシル誘導体 |
LT2810937T (lt) | 2012-01-31 | 2017-02-10 | Daiichi Sankyo Company, Limited | Piridono darinys |
WO2013162061A1 (ja) | 2012-04-26 | 2013-10-31 | 第一三共株式会社 | 二環性ピリミジン化合物 |
JP6284949B2 (ja) | 2013-01-02 | 2018-02-28 | ハー・ルンドベック・アクチエゼルスカベット | Lrrk2阻害剤としてのアミノピリジン誘導化合物 |
-
2014
- 2014-11-26 BR BR112016012146-5A patent/BR112016012146B1/pt active IP Right Grant
- 2014-11-26 CN CN201480065032.8A patent/CN105764514B/zh active Active
- 2014-11-26 KR KR1020167016444A patent/KR102398473B1/ko active IP Right Grant
- 2014-11-26 MX MX2016006815A patent/MX2016006815A/es active IP Right Grant
- 2014-11-26 WO PCT/US2014/067709 patent/WO2015081257A2/en active Application Filing
- 2014-11-26 JP JP2016534735A patent/JP6496731B2/ja active Active
- 2014-11-26 EP EP14819178.6A patent/EP3074390B1/en active Active
- 2014-11-26 AU AU2014354711A patent/AU2014354711B2/en active Active
- 2014-11-26 CN CN201910548630.5A patent/CN110156770B/zh active Active
- 2014-11-26 US US15/039,609 patent/US10233176B2/en active Active
- 2014-11-26 CA CA2930324A patent/CA2930324C/en active Active
-
2016
- 2016-05-16 IL IL245660A patent/IL245660B/en active IP Right Grant
- 2016-05-25 MX MX2020005181A patent/MX2020005181A/es unknown
-
2019
- 2019-01-22 US US16/254,208 patent/US10723725B2/en active Active
-
2020
- 2020-06-11 US US16/899,494 patent/US11034686B2/en active Active
- 2020-06-11 US US16/899,489 patent/US11034685B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3074390B1 (en) | 2020-07-08 |
US11034686B2 (en) | 2021-06-15 |
CN105764514B (zh) | 2019-07-12 |
CN105764514A (zh) | 2016-07-13 |
EP3074390A2 (en) | 2016-10-05 |
KR20160091358A (ko) | 2016-08-02 |
WO2015081257A2 (en) | 2015-06-04 |
BR112016012146A2 (pt) | 2017-08-08 |
JP6496731B2 (ja) | 2019-04-03 |
KR102398473B1 (ko) | 2022-05-16 |
AU2014354711B2 (en) | 2018-10-25 |
MX2016006815A (es) | 2016-12-02 |
AU2014354711A1 (en) | 2016-06-02 |
IL245660B (en) | 2020-01-30 |
IL245660A0 (en) | 2016-06-30 |
JP2017501981A (ja) | 2017-01-19 |
US20200299287A1 (en) | 2020-09-24 |
US20200299288A1 (en) | 2020-09-24 |
US20170022189A1 (en) | 2017-01-26 |
CA2930324C (en) | 2022-01-18 |
US10233176B2 (en) | 2019-03-19 |
CA2930324A1 (en) | 2015-06-04 |
WO2015081257A3 (en) | 2015-07-02 |
US20190152965A1 (en) | 2019-05-23 |
CN110156770B (zh) | 2022-10-04 |
CN110156770A (zh) | 2019-08-23 |
MX2020005181A (es) | 2020-08-17 |
BR112016012146B1 (pt) | 2022-11-01 |
US10723725B2 (en) | 2020-07-28 |
US11034685B2 (en) | 2021-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016012146A8 (pt) | derivados de aminopiridina como inibidores de quinase da família tam | |
FR21C1059I2 (fr) | Compositions pharmaceutiques | |
DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
PH12019500176A1 (en) | Heterocyclic compounds and ther uses | |
PH12016500739A1 (en) | Inhibitors of the fibrolast growth factor receptor | |
CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2015003280A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
CR20150263A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasas | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
TR201811764T4 (tr) | Kinaz inhibitörleri olarak aminoheteroaril benzamidleri. | |
UY35500A (es) | Indazoles sustituidos con heteroarilo | |
DK3030262T3 (da) | Kombineret farmaceutisk sammensætning | |
UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
UY35499A (es) | Indazoles sustituidos con diaminoheteroarilo | |
DK3060200T3 (da) | Tyrosinderivater og sammensætninger dermed | |
MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
CL2017000587A1 (es) | Derivados de tetrahidroquinolina como inhibidores de bromodominio | |
BR112017012005A2 (pt) | compostos orgânicos | |
GT201600252A (es) | Derivados de naftiridinadiona | |
MX363631B (es) | Composiciones y metodos para tratar infecciones bacterianas. | |
MX2015016603A (es) | Composiciones de corticosteroides. | |
BR112015016741A2 (pt) | composição, dispositivo e sistema |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/11/2014, OBSERVADAS AS CONDICOES LEGAIS |